Two new drugs for HIV infection

Med Lett Drugs Ther. 2008 Jan 14;50(1277):2-4.
No abstract available

MeSH terms

  • Administration, Oral
  • CCR5 Receptor Antagonists
  • Cyclohexanes / administration & dosage
  • Cyclohexanes / adverse effects
  • Cyclohexanes / economics
  • Cyclohexanes / therapeutic use*
  • Drug Administration Schedule
  • Drug Costs
  • Drug Interactions
  • Drug Resistance, Viral
  • HIV Fusion Inhibitors / administration & dosage
  • HIV Fusion Inhibitors / adverse effects
  • HIV Fusion Inhibitors / economics
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / adverse effects
  • HIV Integrase Inhibitors / economics
  • HIV Integrase Inhibitors / therapeutic use*
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • Humans
  • Maraviroc
  • Organic Chemicals / administration & dosage
  • Organic Chemicals / adverse effects
  • Organic Chemicals / economics
  • Organic Chemicals / therapeutic use*
  • Pyrrolidinones
  • Raltegravir Potassium
  • Treatment Outcome
  • Triazoles / administration & dosage
  • Triazoles / adverse effects
  • Triazoles / economics
  • Triazoles / therapeutic use*

Substances

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Fusion Inhibitors
  • HIV Integrase Inhibitors
  • Organic Chemicals
  • Pyrrolidinones
  • Triazoles
  • Raltegravir Potassium
  • Maraviroc